Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Trump Announces U.S.–India Trade Deal Cutting Tariffs, Boosting Markets and Energy Ties 
Japan Finance Minister Defends PM Takaichi’s Remarks on Weak Yen Benefits 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
U.S. Stock Futures Rise as Investors Eye Big Tech Earnings and AI Momentum 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
JPMorgan Lifts Gold Price Forecast to $6,300 by End-2026 on Strong Central Bank and Investor Demand 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Taiwan Urges Stronger Trade Ties With Fellow Democracies, Rejects Economic Dependence on China 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
India Budget 2025 Highlights Manufacturing Push but Falls Short of Market Expectations 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
